Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the performance and pricing of its key product, Pylarify, which has led to significant stock price declines [3]. Group 1: Legal Action - The Portnoy Law Firm is advising Lantheus investors who purchased securities between February 26, 2025, and August 5, 2025, to file a lead plaintiff motion by November 10, 2025 [1]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Impact - The complaint claims that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, asserting that market leadership and premium pricing would support revenue growth while concealing competitive pressures [3]. - Following the release of quarterly results in May and August 2025, which showed sharp sales declines and reduced guidance, Lantheus' stock dropped over 23% and 28% respectively [3].

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Lantheus business and prospects, resulting in its stock trading at inflated prices. ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Lantheus securities between February 26, 2025, and August 5, 2025 [2]. Case Details - The Complaint alleges that Lantheus made materially false and misleading statements, including: - Providing overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The early 2025 price increase, despite prior price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and revenue [3]. - Defendants' statements regarding the Company's business and prospects were materially false and misleading [3]. Next Steps - Investors who suffered losses in Lantheus have until November 10, 2025, to request to be appointed as lead plaintiff in the case [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025. Lantheus describes itself as a "global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products.†For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. ...

Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims centered around misleading information regarding the company's revenue outlook and market dynamics for its key product, Pylarify [1][4]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with Pylarify being a significant product used for prostate cancer diagnosis and treatment [3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives misrepresented the company's revenue projections and downplayed risks related to competition, pricing, and macroeconomic factors [4]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing earnings reports [4][5]. Financial Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [6]. Legal Process - Investors who purchased Lantheus securities during the specified class period (February 26, 2025, to August 5, 2025) have until November 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly providing misleading information to investors regarding the competitive position of its product Pylarify during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1 - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's competitive dynamics [2]. - It is alleged that the company was not adequately equipped to assess pricing and competition for Pylarify, which led to a risk of price erosion and affected revenue and growth potential [2]. - The complaint states that these misleading statements resulted in shareholders purchasing Lantheus securities at artificially inflated prices [2]. Group 2 - Investors who acquired shares of Lantheus are encouraged to contact the law firm before the lead plaintiff motion deadline on November 10, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation process [3].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during the specified class period [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2][3]. Group 2: Financial Impact and Stock Performance - Following disappointing results announced on August 6, 2025, Lantheus reported an 8.3% year-over-year decline in Pylarify's performance and significantly reduced its growth projections for fiscal year 2025 [4]. - The announcement led to a sharp decline in Lantheus' stock price, dropping from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, representing a decline of approximately 28.8% in one day [4].

LOS ANGELES--(BUSINESS WIRE)---- $LNTH--LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

ATLANTA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). The lawsuit alleges, among other things, that Defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. If you purchased shares o ...